Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Other Non-Current Liabilities (2022 - 2024)

NewAmsterdam Pharma (NAMS) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $18.8 million as the latest value for Q3 2024.

  • Quarterly Other Non-Current Liabilities changed N/A to $18.8 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $18.8 million through Sep 2024, changed N/A year-over-year, with the annual reading at $7.8 million for FY2023, 3.54% up from the prior year.
  • Other Non-Current Liabilities hit $18.8 million in Q3 2024 for NewAmsterdam Pharma, up from $13.4 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $18.8 million in Q3 2024 to a low of $7.5 million in Q4 2022.
  • Historically, Other Non-Current Liabilities has averaged $12.8 million across 3 years, with a median of $13.4 million in 2024.
  • Biggest YoY gain for Other Non-Current Liabilities was 3.54% in 2023; the steepest drop was 3.54% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $7.5 million in 2022, then rose by 3.54% to $7.8 million in 2023, then surged by 141.5% to $18.8 million in 2024.
  • Business Quant data shows Other Non-Current Liabilities for NAMS at $18.8 million in Q3 2024, $13.4 million in Q2 2024, and $16.5 million in Q1 2024.